3. Treatment of ACS Part 2 (Working Diagnosis of STEMI vs NSTE ACS, Arabic Version)

  Рет қаралды 1,917

CardioMinds, Dr. Sherif Altoukhy

CardioMinds, Dr. Sherif Altoukhy

Күн бұрын

In this video, the specific recommedations regarding the indications for revascularization and for pharmacotherapy are compared in the working diagnosis of STEMI vs. NSTE-ACS.
0:00 Reperfusion Indications in STEMI
9:17 Pharmacotherapy in STEMI
12:49 Fibrinolytic Therapy for STEMI
19:53 Reperfusion Indications in NSTE-ACS
22:53 Pharmacotherapy in NSTE-ACS
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
www.escardio.org/Guidelines/C...
2023 ESC Guidelines for the management of acute coronary syndromes Supplementary data
oup.silverchair-cdn.com/oup/b...
Percutaneous Myocardial Revascularization in Late-Presenting Patients With STEMI
pubmed.ncbi.nlm.nih.gov/34556...
Mechanical Reperfusion and Long-term Mortality in Patients With Acute Myocardial Infarction Presenting 12 to 48 Hours From Onset of Symptoms.
jamanetwork.com/journals/jama...
Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial
www.ncbi.nlm.nih.gov/pmc/arti...
ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up
pubmed.ncbi.nlm.nih.gov/25161...
Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. STREAM trial
www.nejm.org/doi/full/10.1056...
Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme
pubmed.ncbi.nlm.nih.gov/31539...
ISAR-REACT 5 trial. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
pubmed.ncbi.nlm.nih.gov/31475...
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction
pubmed.ncbi.nlm.nih.gov/11530...
GRACE ACS Risk and Mortality Calculator
www.mdcalc.com/calc/1099/grac...

Пікірлер: 1
@mahmoud27898
@mahmoud27898 3 ай бұрын
Thanks
4. Treatment of ACS-Part 3 (Triple Antithrombotic Therapy & Alternative Strategies, Arabic Version)
27:31
3. Treatment of ACS-Part 2 (Working Diagnosis of STEMI vs NSTE ACS, English Version)
26:51
CardioMinds, Dr. Sherif Altoukhy
Рет қаралды 382
DO YOU HAVE FRIENDS LIKE THIS?
00:17
dednahype
Рет қаралды 97 МЛН
Red❤️+Green💚=
00:38
ISSEI / いっせい
Рет қаралды 20 МЛН
DEFINITELY NOT HAPPENING ON MY WATCH! 😒
00:12
Laro Benz
Рет қаралды 46 МЛН
아이스크림으로 체감되는 요즘 물가
00:16
진영민yeongmin
Рет қаралды 55 МЛН
7. MINOCA vs. Type 2 MI (Arabic Version)
20:45
CardioMinds, Dr. Sherif Altoukhy
Рет қаралды 1,4 М.
8. Technical Aspects of Invasive Strategy in ACS (Arabic Version)
28:13
CardioMinds, Dr. Sherif Altoukhy
Рет қаралды 1,1 М.
6. Complications of ACS (Arabic Version)
41:45
CardioMinds, Dr. Sherif Altoukhy
Рет қаралды 1,5 М.
Hyponatremia
15:24
Dirty Medicine
Рет қаралды 73 М.
Coronary angiographic views- Elias Hanna
1:09:22
Elias Hanna
Рет қаралды 148 М.
8. Technical Aspects of Invasive Strategy in ACS (Arabic Version)
26:56
CardioMinds, Dr. Sherif Altoukhy
Рет қаралды 353
2. Treatment of ACS-Part 1 (General Lines & Antithrombotic Therapy, Arabic Version)
27:27
CardioMinds, Dr. Sherif Altoukhy
Рет қаралды 2,8 М.
7. MINOCA vs. Type 2 MI (English Version)
19:28
CardioMinds, Dr. Sherif Altoukhy
Рет қаралды 375
DO YOU HAVE FRIENDS LIKE THIS?
00:17
dednahype
Рет қаралды 97 МЛН